Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peltola, J.
Right arrow Articles by Elovaara, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peltola, J.
Right arrow Articles by Elovaara, I.
Neurology 2001;57:895-896
© 2001 American Academy of Neurology
Brief Communications

Increased nitric oxide products in CSF in primary progressive MS may reflect brain atrophy

Jukka Peltola, MD;, Maritta Ukkonen, MD;, Eeva Moilanen, MD, PhD; and Irina Elovaara, MD, PhD

From the Neuroimmunology Unit (Drs. Peltola, Ukkonen, and Elovaara), Department of Neurology, Tampere University Hospital; and The Immunopharmacological Research Group (Dr. Moilanen), University of Tampere Medical School and Tampere University Hospital, Tampere, Findland.

Address correspondence and reprint requests to Dr. Jukka Peltola, Department of Neurology, Tampere University Hospital, P.O. Box 2000, Tampere, FIN 33521, Finland; e-mail: jukka.peltola{at}tays.fi

Because nitric oxide (NO) is a putative mediator of oligodendrocyte damage in the primary progressive form of MS (PPMS), the authors analyzed the levels of NO oxidation products in CSF and plasma from 25 patients with PPMS and 15 controls. The levels of nitrite + nitrate (NOx) in CSF were fourfold higher in patients with PPMS than in controls (p < 0.001), whereas the concentrations in plasma were similar. These data suggests involvement of NO in nervous tissue damage in PPMS.




This article has been cited by other articles:


Home page
 Mult SclerHome page
K. Rejdak, A. Petzold, Z. Stelmasiak, and G. Giovannoni
Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis
Multiple Sclerosis, January 1, 2008; 14(1): 59 - 66.
[Abstract] [PDF]

Home page
 NeurologyHome page
K. Rejdak, M. J. Eikelenboom, A. Petzold, E. J. Thompson, Z. Stelmasiak, R. H.C. Lazeron, F. Barkhof, C. H. Polman, B. M.J. Uitdehaag, and G. Giovannoni
CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis
Neurology, October 26, 2004; 63(8): 1439 - 1445.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
R. Hohlfeld
Immunologic factors in primary progressive multiple sclerosis
Multiple Sclerosis, June 1, 2004; 10(1_suppl): S16 - S22.
[Abstract] [PDF]

Home page
 Mult SclerHome page
C. Lucchinetti and W. Bruck
The pathology of primary progressive multiple sclerosis
Multiple Sclerosis, June 1, 2004; 10(1_suppl): S23 - S30.
[Abstract] [PDF]

Home page
 Mult SclerHome page
R. Hohlfeld
Immunologic factors in primary progressive multiple sclerosis
Multiple Sclerosis, May 1, 2004; 10(3_suppl): S16 - S22.
[Abstract] [PDF]

Home page
 Mult SclerHome page
C. Lucchinetti and W. Bruck
The pathology of primary progressive multiple sclerosis
Multiple Sclerosis, May 1, 2004; 10(3_suppl): S23 - S30.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by AAN Enterprises, Inc.